Home Health Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs.

Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs.

Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs. Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs. Reviewed by Health And Fitness on July 13, 2018 Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )

Recent Comments

Powered by Blogger.